Lipitor (Atorvastatin)

Atorvastatin is indicated for several lipid‑related conditions and for prevention of cardiovascular disease.

• Hypercholesterolemia: reduces LDL‑cholesterol and total cholesterol levels.
• Primary prevention of cardiovascular disease: lowers risk of heart attack and stroke in at‑risk patients.
• Secondary prevention of cardiovascular disease: decreases recurrence of cardiovascular events after a prior event.
• Mixed dyslipidemia: improves lipid profile by lowering triglycerides and raising HDL‑cholesterol.
• Familial hypercholesterolemia: provides significant LDL‑cholesterol reduction in genetically high‑cholesterol patients.

• Atorvastatin competitively inhibits HMG‑CoA reductase, the key enzyme that catalyzes the conversion of HMG‑CoA to mevalonate in the hepatic cholesterol biosynthesis pathway. By blocking this rate‑limiting step, intracellular cholesterol synthesis falls, prompting up‑regulation of LDL receptors on hepatocyte surfaces. The increased receptor density enhances clearance of circulating low‑density lipoprotein particles, thereby lowering plasma LDL‑cholesterol and improving overall lipid profiles.

Atorvastatin may be associated with a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects

• Headache: mild to moderate intensity.
• Muscle pain (myalgia): aching or soreness without weakness.
• Abdominal discomfort: including nausea or dyspepsia.
• Constipation or diarrhea: changes in bowel habits.
• Elevated liver enzymes: mild, transient increases in ALT/AST.

Serious or Rare Side Effects

• Rhabdomyolysis: severe muscle breakdown with risk of renal failure.
• Significant liver injury: marked elevation of transaminases or hepatitis.
• Severe allergic reactions: rash, angioedema, or anaphylaxis.
• Myopathy with weakness: muscle weakness accompanied by elevated CK.
• Pancreatitis: acute inflammation of the pancreas.

Before initiating atorvastatin therapy, several precautionary measures should be considered to ensure safe use.

• Liver function monitoring: assess baseline ALT/AST and repeat periodically.
• Muscle symptom assessment: evaluate for unexplained muscle pain, tenderness, or weakness.
• Drug interaction review: avoid concomitant use with strong CYP3A4 inhibitors.
• Renal impairment caution: adjust therapy in patients with severe kidney disease.
• Pregnancy and lactation: discontinue if pregnancy is confirmed or if breastfeeding.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Atorvastatin interacts with several medicines; some require avoidance while others need careful monitoring.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, HIV protease inhibitors): can markedly increase atorvastatin plasma levels.
• Gemfibrozil: raises risk of myopathy and rhabdomyolysis.
• Cyclosporine: enhances statin exposure and muscle toxicity.
• Colchicine (high dose): increases risk of severe muscle injury.

Moderate Interactions (Monitor Closely)

• Warfarin: may potentiate anticoagulant effect, requiring INR monitoring.
• Digoxin: slight increase in serum concentrations.
• Antacids containing aluminum or magnesium: may reduce absorption, monitor lipid response.
• Grapefruit juice: can modestly raise atorvastatin levels.